Eyes have been turned towards AstraZeneca and its Q1 update this week, but a look at the rest of our FTSE 100 pharmaceuticals firms shows something perhaps surprising.
GlaxoSmithKline (LSE: GSK)(NYSE: GSK.US) has long been the benchmark against which the others are judged, but over the past 12 months its shares have been soundly beaten by Shire (LSE: SHP) and Hikma Pharmaceuticals (LSE: HIK).
While Glaxo has dropped 7% to todays 1,524p, Hikma has gained an impressive 36% to 2,143p. Shire, meanwhile, has soared by 73% to 5,570p, even after Novembers slump when the approach from AbbVie was called off. So what have the two smaller companies been doing right?
Part if it is indeed down to size, and a successful new drug for Shire could make a proportionately bigger difference than a new product set against the background of Glaxos huge portfolio. In fact, in 2014 Shire reported record revenue, up 23% to $5.8bn, with record non-GAAP earnings. The firm told is it was starting 2015 with its strongest-ever pipeline, after CEO Flemming Ornskov had said that 2014 was a transformational year for Shire.
With a forward P/E of 22 for 2015, dropping to 19 a year later, and very little in the way of dividends right now, Shire is clearly priced as a growth stock. But its growth premium is not all that stretching, and a few good pipeline years could generate a lot of wealth.
Another great year
Hikma also had a pretty good 2014, recording a relatively modest 9% revenue growth, but a more impressive 30% rise in EPS. And where the bigger companies are suffering from the loss of patent protection and subsequent competition from cheaper substitutes, Hikmas Generics division is cashing in, although 2014 did see a fall in Generics revenue. CEO Said Darwazah told us that Our global Injectables business was the key growth driver this year, demonstrating the attractiveness of our product portfolio in the US
Hikma is also priced for growth, with almost exactly the same forecast P/E ratios as Shire, and only slightly higher dividends.
GlaxoSmithKline, on the other hand, is looking very much like the classic mature blue-chip company, able to turn most of its earnings over to dividends to provide forecast yields of 5.1% this year and next. And its P/E is only a little over the long-term FTSE average at 17 this year dropping to 16 next. Its vital that dividend cover does not drop too low, but with a number of positive updates coming from the firms pipeline in the past few months, the cash looks safe.
Which is best?
Which should you buy? I reckon youd get a very nice income stream from Glaxo over the next few decades, and the shares are good value at todays price. But if you fancy a bit more excitement with the possibility of stronger growth, Shire and Hikma deserve serious consideration.
If you agree that smaller companies can offer better growth prospects than their bigger cousins, check out our hot new report that identifies 1 Top Small-Cap Stock From The Motley Fool. It’s a smaller company that has already rewarded its shareholders with a stonking performance, yet the Motley Fool’s top analysts reckon there could be a further 45% upside to come.
Want to know the name of this potential small-cap winner? Just click here to get your completely free report today.
A Top Small-Cap Recommendation from The Motley Fool!
Sometimes you need to go beyond the FTSE 100 to find the potential big winners of tomorrow.
Thats why our team of ace team of Motley Fool investors are taking a closer look at some of the smaller, lesser-known companies that trade on the wider market.
And right now, theyve zoomed in on one stock that they think particularly deserves your attention. To discover the identity of this exciting small-cap play
Alan Oscroft has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline and Hikma Pharmaceuticals. We Fools don’t all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.